| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
11-19-2011, 08:23 PM
|
#1 | |||
|
||||
|
Senior Member
|
MedGenesis Therapeutix Reacquires Rights for GDNF
8 Nov 2010 - MedGenesis... announced today that it has regained all rights to glial cell line-derived neurotrophic factor (GDNF) protein and related Convection Enhanced Delivery (CED) technology from Biovail Laboratories International SRL... MedGenesis and BLS agreed to conclude their previously established collaboration to develop and commercialize GDNF, returning the product to MedGenesis together with a one-time cash payment of $5 million to accelerate the development of GDNF in Parkinson’s disease. At the same time, MedGenesis has broadened GDNF applications to hearing loss and epilepsy. http://www.medgenesis.com/news.htm (I have no idea how this impacts the "development of GDNF in Parkinson's Disease". MJF was listed as one of the funding partners--any comment about this news? does it matter? thanks, madelyn)
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson Last edited by olsen; 11-20-2011 at 01:09 AM. |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Aav2-gdnf | Parkinson's Disease Clinical Trials | |||
| gdnf...it's back? | Parkinson's Disease | |||
| The return of gdnf | Parkinson's Disease | |||
| Gdnf | Parkinson's Disease | |||
| The GDNF fiasco | Parkinson's Disease | |||
MedGenesis Therapeutix Reacquires Rights for GDNF
Linear Mode
